World Pharma News Projects at the 2nd Annual Pharma Corporate Communications Conference

The 2nd Annual Pharma Corporate Communications Conference in Rome (9th & 10th April, 2008) confirmed once more that Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. World Pharma News projects for the first time have been presented and described in the frames of an international event. The 2nd Annual Pharma Corporate Communications Conference offered a great opportunity:
  • to present the World Pharma News communication (web based) research;
  • to describe some expectations, and in special;
  • to share the achieved experience and the learned lessons.

For a little of the Rome event essence which covers only the World Pharma News discussions you are invited to download the World Pharma News presentation. Your comments, suggestions and feedback (as usual) are only welcome.

Presentation overview

  • Trends and opportunities of the web (Internet) communication technologies (Pharma2.0 signs)
  • What is... ?
  • World Pharma News Project background
  • World Pharma News (.net) Project (Web 2.0/Pharma2.0) background
  • Examples, suggestions and concrete actions from the perspective of the web based (online) media through a short survey (assessment test)
  • Where? Why? How?
World Pharma News / Where? Why? How?

Presentation download link: World Pharma News / Where? Why? How? (.pdf, 874 KB)

Related news article:

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...